Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indacaterol Evening Dosing in Moderate to Severe COPD
NCT00615030Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2008
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of indacaterol in chronic obstructive pulmonary disease (COPD) (12 arms), sponsored by Novartis. Primary endpoint: Trough Forced Expiratory Volume in 1 Second at 14 days. Started Jan 2008; status: completed.
02
Drugs
indacaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00615030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00615030.